Table 2.
Linear models for 25(OH)D levels (ng/mL) at baseline and at week 24 for responders (n = 52)
| Part A. | ||
| Baseline (n = 97) | ||
| Unadjusted model | Adjusted model | |
| Beta (95 % CI) | Beta (95 % CI) | |
| Female sex | −1.08 (−7.27, 5.12) | −5.57 (−11.40, 0.26) |
| Age (years) | −0.16 (−0.44, 0.11) | −0.20 (−0.46, 0.05) |
| Non-white race/ethnicity | 2.48 (−3.29, 8.25) | 2.64 (−2.78, 8.06) |
| Nadir CD4+ T lymphocyte (per 100 cells/mm3) | 0.57 (−2.04, 3.18) | 1.17 (−1.42, 3.75) |
| Current use of TDF | 5.84 (−0.43, 12.12) | |
| Current use of AZT | −5.27 (−11.44, 0.89) | |
| Current use of EFV | −1.65 (−7.96, 4.66) | |
| Current use of PI | −2.85 (−3.55, 9.30) | 6.93 (0.96, 12.90) |
| Part B. | ||
| Week 24a (n = 52) | ||
| Unadjusted model | Adjusted model | |
| Beta (95 % CI) | Beta (95 % CI) | |
| Female sex | −4.08 (−16.61, 8.46) | −0.96 (−14.20, 12.27) |
| Age (years) | −0.22 (−0.78, 0.33) | 0.21 (−0.38, 0.79) |
| Non-white race/ethnicity | −5.02 (−16.95, 6.91) | −5.53 (−17.82, 6.77) |
| Nadir CD4+ T lymphocyte (per 100 cells/mm3) | 1.94 (−3.44, 7.31) | 3.29 (−1.96, 8.54) |
| Baseline 25(OH)D | 1.17 (0.25, 2.09) | 1.27 (0.24, 2.30) |
| Current use of TDF | −10.24 (−22.50, 2.02) | |
| Current use of AZT | 7.44 (−4.70, 19.57) | |
| Current use of EFV | 17.88 (4.08, 31.68) | 21.09 (6.41, 35.78) |
| Current use of PI | −16.15 (−31.10, −2.13) | |
25(OH)D 25-hydroxyvitamin D, TDF tenofovir, AZT zidovudine, EFV efavirenz, PI protease inhibitor
aFor those who underwent vitamin D supplementation and achieved 25(OH)D levels > 30 ng/mL at week 24
Bold font implies statistically significant results assuming a 5% significance threshold